Clinical Ink Announces Addition of New Module to Their Lumenis™ eSource Ecosystem
Summary
With the addition of eConsent, Clinical Ink’s Lumenis platform expands further, providing purpose-built solutions for your protocol and anytime, anywhere access to study data. The new eConsent module comes just months after the EMA released an important qualification opinion in favor of using eSource DDC in clinical trials. “Lumenis simplifies your study workflow — providing fast, clean data to help you make critical decisions. Not only are your sites and patients assured of an easier experience, but you can be certain your protocol is executed correctly.” Lumenis further elevates each study through experienced support services and customizable solutions for specific therapeutic areas including lupus, gastrointestinal and central nervous system diseases, dermatology, oncology, and many others. Our Lumenis eSource clinical technology and configurable direct data capture, eCOA, ePRO, and eConsent modules — a suite of solutions for capturing and integrating electronic data from sites, clinicians, and patients at its source — naturally enhance your clinical trial workflow by reducing manual labor, providing anytime, anywhere data access, and saving resources as your trials progress.
Classifications
AskAI Classifications
LabelsLinked Companies
